Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.
- DOI
- 10.1016/j.ygyno.2026.08.005
- Published
- 2026 Sep
- Container
- Gynecologic oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ygyno.2026.08.005,
title = {Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.},
author = {Nguyen AQ and Bednarek N and Al-Sawalha I and Nagele B and Moroney F and Lastra JB and Myong S and Hosseinibarkooie S and Weng SHS and Kurnit KC and Yamada SD and Fleming GF and Challa S},
year = {2026},
journal = {Gynecologic oncology},
doi = {10.1016/j.ygyno.2026.08.005},
url = {https://doi.org/10.1016/j.ygyno.2026.08.005}
}RIS
TY - JOUR TI - Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. AU - Nguyen AQ AU - Bednarek N AU - Al-Sawalha I AU - Nagele B AU - Moroney F AU - Lastra JB AU - Myong S AU - Hosseinibarkooie S AU - Weng SHS AU - Kurnit KC AU - Yamada SD AU - Fleming GF AU - Challa S PY - 2026 JO - Gynecologic oncology DO - 10.1016/j.ygyno.2026.08.005 UR - https://doi.org/10.1016/j.ygyno.2026.08.005 ER -
APA
AQ, N., N, B., I, A., B, N., F, M., JB, L., S, M., S, H., SHS, W., KC, K., SD, Y., GF, F., & S, C. (2026). Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2026.08.005
Source records
- pubmed · retrieved 2026-09-26T05:26:03.175Z